SMDG maintains a growing intellectual property (IP) portfolio which includes granted patent and pending applications in the world's major pharmaceutical markets. In addition to the patent portfolio, SMDG also safeguards its intellectual property by maintenance of scientific trade secrets as well as continued in-house discovery projects which together form broad protection for the company's intellectual assets.

 

Key Aspects of SMDG's intellectual property portfolio

​

• Receptor targeted delivery 

• Proprietary Carriers (NLCs) (TM), novel and innovative nanocarriers for delivery of nucleic acid-based therapies and gene therapy- including but not limited to siRNA and antisense oligonucleotides 

• Proprietary Carriers (NLCs) (TM), novel and innovative nanocarriers for delivery of different types of therapeutic molecules

• Tailored targeting technology - directing  to tissues and organs of interest for different disorders

• Proprietary Nanoligand Carriers (NLCs) (TM),  methods – cellular engineering technology, optimization and downstream processing and manufacturing

​

Our Intellectual Property legal teams:

​

​

​

​

​